Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Wednesday 26 August →